NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) raised approximately $80.5 million in a November stock offering, extending its projected cash runway through 2028 as the medical device developer approaches pivotal clinical results for a hypertension treatment being developed with Medtronic plc (NYSE: MDT).
The financing follows completion of patient enrollment in the global Phase 3 BACKBEAT trial evaluating Atrioventricular Interval Modulation Therapy, or AVIM Therapy, in patients with uncontrolled hypertension who have implanted dual-chamber pacemakers.
Orchestra BioMed reported that 349 patients were randomized across 92 clinical sites in 15 countries, exceeding the trial’s enrollment target. The company and Medtronic plan to submit primary endpoint results for consideration as a late-breaking presentation at the Heart Rhythm Society’s annual meeting in May 2027.
The companies are completing three-month patient follow-up and preparing the primary endpoint database for analysis.
The U.S. Food and Drug Administration has confirmed that Medtronic can seek marketing authorization for AVIM Therapy through a supplement to an existing premarket approval, rather than a separate original application.
Medtronic plans to submit the supplement following presentation of the BACKBEAT results, assuming the trial produces positive findings.
“With the completion of enrollment of the BACKBEAT Trial, AVIM Therapy is nearing pivotal primary endpoint results,” said David Hochman, Orchestra BioMed’s chairman and chief executive officer.
AVIM Therapy is designed to lower blood pressure by modifying the timing between atrial and ventricular contractions through an implanted pacemaker. The companies are evaluating the technology as a potential treatment for patients whose hypertension remains uncontrolled despite medication.
Orchestra BioMed closed its underwritten public offering November 9, selling 17.25 million common shares at $5 each. The transaction generated approximately $80.5 million in net proceeds after underwriting discounts, commissions and estimated expenses, including the underwriters’ full exercise of their option to purchase additional shares.
The company held $101.9 million in cash, cash equivalents and marketable securities as of September 30, before receiving the offering proceeds.
Orchestra BioMed expects the combined funding to support operations through 2028, covering anticipated clinical and regulatory milestones for its two principal cardiovascular development programs.
The company reported a third-quarter net loss attributable to common stockholders of $19.6 million, or $0.30 per share, compared with $20.8 million, or $0.40 per share, a year earlier.
Research and development expenses increased 26% to $17.7 million from $14 million, reflecting higher spending on the BACKBEAT trial and development of the company’s Virtue Sirolimus AngioInfusion Balloon, known as Virtue SAB.
Selling, general and administrative expenses declined 21% to $5.6 million from $7.1 million, primarily because of lower legal and professional fees.
Net cash used in operating activities and fixed-asset purchases increased to $19.9 million from $14.9 million in the year-earlier quarter, driven by clinical trial costs and personnel and consulting expenses.
Quarterly net interest expense rose to $3.4 million from $1.2 million, while noncash stock-based compensation declined to $2.3 million from $3 million.
Orchestra BioMed’s second pivotal-stage program, Virtue SAB, is being evaluated in a U.S. clinical trial for coronary in-stent restenosis, a condition in which an artery narrows again after treatment with a stent.
The randomized, single-blind Virtue trial is comparing the investigational device with the commercially available AGENT paclitaxel-coated balloon.
The study is designed to enroll approximately 740 patients, with enrollment expected to conclude by the end of 2027. Orchestra BioMed reported accelerating clinical site activation and patient recruitment.
Virtue SAB uses a balloon-based system to deliver liquid sirolimus directly into the arterial wall rather than relying on a drug coating on the balloon surface.
The company presented additional preclinical and clinical evidence supporting the technology at the Transcatheter Cardiovascular Therapeutics conference November 1.
Separately, Orchestra BioMed received a $6.1 million milestone payment September 14 related to Haemonetics Corp.’s (NYSE: HAE) acquisition of Vivasure Medical Ltd.
Combined with approximately $5 million received in January, proceeds associated with the transaction totaled approximately $11 million during 2026.
The FDA recently approved Vivasure’s PerQseal Elite vascular closure system for large-bore arterial procedures.
Orchestra BioMed also scheduled an investor research and development presentation for November 12 in New York City, featuring physician investigators discussing the clinical programs and potential applications of AVIM Therapy and Virtue SAB.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
